The University of Iowa

Clinical Lecture Series: Issues in Clinical Trial Agreements (Nov 2)

Clinical Lecture Series

Thursday, November 2, 2017 | Noon — 1:00 PM | C44-A GH  

Jessica Boyle, JD

Working with DSP (Division of Sponsored Programs): Issues in Clinical Trial Agreements

The Division of Sponsored Programs (DSP) will present "Working with DSP: Issues in Clinical Trial Agreements” where topics will include DSP’s role in reviewing, negotiating and legally executing corporate funded clinical trial agreements. 

CME and IBN credits are available. You must have a badge to receive credits. Scanning will be conducted 11:50 AM – 12:10 PM only.

Continuing Medical Education Information

Target Audience: Health professionals working on human subjects research.

Educational Objectives: Participants should be able to discuss the most current information and relevant approaches to research involving human subjects.

The purpose of this lecture series is to educate clinical research professionals on the basics of clinical research. There are also courses of interest on current and novel research. Taken together, the lectures in this series will help provide a more effective, efficient and cohesive clinical research environment at the University of Iowa.


CME ACCREDITATION: The University of Iowa Roy J. and Lucille A. Carver College of Medicine is accredited by the Accreditation Council for Continuing Medical Education(ACCME) to provide continuing medical education for physicians.


CME CREDIT DESIGNATION: The University of Iowa Carver College of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


The University of Iowa College of Nursing is an Iowa Board of Nursing approved provider, Number 1. Full time attendance for this program will award 1.2 contact hours.

Everyone in a position to control the content of this educational activity will disclose to the CME provider and to attendees all relevant financial relationships with any commercial interest. They will also disclose if any pharmaceuticals or medical procedures and devices discussed are investigational or unapproved for use by the U.S. Food and Drug Administration (FDA).